



1645 3700

0300  
+ Box 508

Please type a plus sign (+) inside this box → ☒

PTO/SB/21 (6-98)  
Approved for use through 09/30/2000. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	<b>Application Number</b>	09/683,258	
	<b>Filing Date</b>	12/05/2001	
	<b>First Named Inventor</b>	kemin Zhou	
	<b>Group Art Unit</b>	1645	
	<b>Examiner Name</b>	unknown	
<b>Total Number of Pages in This Submission</b>	12	<b>Attorney Docket Number</b>	3418

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form  <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment / Response  <input type="checkbox"/> After Final  <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input type="checkbox"/> Information Disclosure Statement          <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/ Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application)  <input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition  <input type="checkbox"/> Petition to Convert to a Provisional Application  <input checked="" type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Small Entity Statement          <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):  1) Copy of Notice to Comply with Sequence Listing Requirement. 2) Response to Notice to Comply with Sequence Listing Requirement. 3) Diskette with electronic copy of Sequence Listing. 3) Statement under 37 CFR 3.73(b) 4) Return postcard.
<b>Remarks</b>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Leticia Reyes Block
Signature	<i>Leticia Reyes Block</i>
Date	09-20-2002

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: <u>9/20/02</u>			
Typed or printed name	<i>Leticia Reyes Block</i>		
Signature	<i>Leticia Reyes Block</i>	Date	<u>9/20/02</u>

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



#8  
PATENT  
Atty. Docket No. 3418

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kemin Zhou

Examiner: Unknown

Serial No: 09/683,258

Group Art Unit: 1645

Filing Date: Dec. 5, 2001

Title: LARGE SCALE PROTEIN  
NUCLEIC ACID INTERACTION  
PROFILING

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS OF 37 C.F.R. 1.821-1.825

Commissioner for Patents  
Washington, D.C. 20231

Sir:

This document is submitted in response to the Notice to Comply with the Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed September 13, 2002.

Transmitted herewith is a substitute copy of the "Sequence Listing" in electronic form. As required by 37 C.F.R. 1.825(d), Applicant's Agent hereby states that the contents of this "Sequence Listing" in electronic form, is identical to the original "Sequence Listing" submitted on May 1<sup>st</sup>, 2002. As required by 37 1.821(f), Applicant's Agent hereby states that the content of this "Sequence Listing" in electronic form and the "Sequence Listing" in paper form submitted on May 1<sup>st</sup>, 2002 are the same and, as required by 37 C.F.R. 1.821(g), also states that the submission includes no new matter.



Atty. Docket No. 3416

Applicant believes that no fee is required for submission of this response. However, if a fee is required, the Commissioner is authorized to deduct such fee from Deposit Account No. 01-0431. This Transmittal Letter is submitted in duplicate for accounting purposes.

Respectfully submitted,

Date: 09-20-2002

Leticia Reyes Block

Leticia Reyes Block  
Reg. No. 50,167

Legal Department  
Affymetrix, Inc.  
3380 Central Expressway  
Santa Clara, CA 95051  
Tel: 408/731-5000/Fax: 408/731-5392



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/683,258	12/05/2001	Kemin Zhou	3418

22886  
AFFYMETRIX, INC  
ATTN: CHIEF IP COUNSEL, LEGAL DEPT.  
3380 CENTRAL EXPRESSWAY  
SANTA CLARA, CA 95051

CONFIRMATION NO. 1011

## FORMALITIES LETTER



Date Mailed: 09/13/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE